Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;99(3):539-42.
doi: 10.1111/j.1349-7006.2007.00712.x. Epub 2008 Jan 14.

Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer

Takuya Akashi  1 , Keiichi Koizumi, Koichi Tsuneyama, Ikuo Saiki, Yasuo Takano, Hideki Fuse
Affiliations

Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer

Takuya Akashi et al. Cancer Sci. 2008 Mar.

Abstract

The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human cancers and has also been shown to participate in the development of cancer metastasis. The present study was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with a high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer treated with androgen-withdrawal therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CXCR4 expression in prostate cancer (with bone metastasis) (×200). The evaluations were recorded as the percentage of positively stained tumor cells in each of three intensity categories: sporadic, 0–5%; focal, 6–50%; and diffuse, 51–100%.
Figure 2
Figure 2
Kaplan–Meier cause‐specific survival curves for patients with metastatic prostate cancers relative to clinicopathological features. (a) Cancer‐specific survival according to pretreatment Gleason score. Solid and dotted lines represent Gleason score <8 (n = 21) and = 8 (n = 31), respectively; P = 0.0025. (b) Cancer‐specific survival according to extent of disease (EOD). Solid and dotted lines represent EOD 0–2 (n = 32) and EOD 3–4 (n = 20), respectively; P = 0.0891. (c) Cancer‐specific survival according to clinical response to hormonal therapy. Solid and dotted lines represent complete response (n = 32), and partial response, no change, and progressive disease (n = 20), respectively; P = 0.0257. (d) Cancer‐specific survival according to CXCR4 expression. Solid and dotted lines represent CXCR4 expression of low (sporadic and focal, n = 34) and high (diffuse, n = 18), respectively; P = 0.0159.
See this image and copyright information in PMC

References

    1. Zlotnik A, Yoshie O. Chemokines. a new classification system and their role in immunity. Immunity 2000; 12: 121–7. - PubMed
    1. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999; 72: 209–53. - PubMed
    1. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of stromal cell‐derived factor‐1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832–7. - PubMed
    1. Muller A, Homey B, Soto H et al . Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–6. - PubMed
    1. Spano JP, Andre F, Morat L, Sabatier L et al . Chemokine receptor CXCR4 and early‐stage non‐small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004; 15: 613–17. - PubMed